| Literature DB >> 34708447 |
Ming-Yen Lin1,2, Sheng-Wen Niu3,4, Wei-Ming Li5,6,7, Huei-Lan Lee8, Li-Tzong Chen9,10,11, Wen-Jeng Wu5,6,7, Shang-Jyh Hwang1,2,4,12.
Abstract
OBJECTIVES: To assess temporal patterns and regional differences in the incidence rate, and factors associated with survival of urinary tract urothelial carcinoma.Entities:
Keywords: geographic variation; incidence; survival; trends; upper tract urothelial carcinoma
Mesh:
Year: 2021 PMID: 34708447 PMCID: PMC9298349 DOI: 10.1111/iju.14731
Source DB: PubMed Journal: Int J Urol ISSN: 0919-8172 Impact factor: 2.896
Age‐standardized incidence rate ratio of UTUC for sex (female‐to‐male) comparison
| Calendar year | Female | Male | Standardized rate ratio (95% CI) |
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Case | Person‐years | CR | SR | Case | Person‐years | CR | SR | |||
| 2001 | 379 | 10 924 270 | 3.47 | 2.84 | 327 | 11 416 850 | 2.86 | 3.45 | 2.56 (1.05–1.41) | 0.005 |
| 2002 | 383 | 10 999 642 | 3.48 | 2.68 | 318 | 11 463 530 | 2.77 | 3.40 | 3.09 (1.09–1.47) | 0.001 |
| 2003 | 416 | 11 062 427 | 3.76 | 3.14 | 382 | 11 500 236 | 3.32 | 3.54 | 1.70 (0.98–1.3) | 0.05 |
| 2004 | 436 | 11 118 512 | 3.92 | 2.99 | 375 | 11 528 324 | 3.25 | 3.52 | 2.30 (1.02–1.35) | 0.01 |
| 2005 | 479 | 11 177 740 | 4.29 | 2.97 | 375 | 11 552 013 | 3.25 | 3.72 | 3.25 (1.09–1.43) | 0.001 |
| 2006 | 522 | 11 246 382 | 4.64 | 3.40 | 449 | 11 577 073 | 3.88 | 3.89 | 2.08 (1.01–1.3) | 0.02 |
| 2007 | 517 | 11 317 207 | 4.57 | 3.42 | 459 | 11 600 237 | 3.96 | 3.69 | 1.17 (0.95–1.22) | 0.12 |
| 2008 | 553 | 11 380 137 | 4.86 | 3.09 | 425 | 11 617 559 | 3.66 | 3.77 | 3.04 (1.07–1.38) | 0.001 |
| 2009 | 543 | 11 446 859 | 4.74 | 3.20 | 459 | 11 631 543 | 3.95 | 3.55 | 1.62 (0.98–1.26) | 0.05 |
| 2010 | 563 | 11 504 968 | 4.89 | 3.22 | 470 | 11 635 980 | 4.04 | 3.58 | 1.67 (0.98–1.26) | 0.05 |
| Estimated APC (95% CI) | 4.28 (−6.11, 15.83) | 1.69 (−10.06, 14.96) | 4.14 (−7.26, 16.94) | 0.68 (−10.12, 12.79) | ||||||
The estimated APC with 95% CIs was assessed by a generalized linear model with a log‐linear link and assuming Poisson distribution.
Statistical significance that was tested by Z‐test (P < 0.05).
Unit of incident rate: per 100 000 person‐years.
Annual incidence rate was standardized by the age distribution (<45, 45–54, 55–64, 65–‐74, ≥75 years) of World Health Organization’s 2000 standard population.
Fig. 1Sex‐specific incidence of UTUC by age in 2001–2010.
Fig. 2Trends in age‐standardized incidence rates for UTUC in 2001–2010. The annual incidence rate was standardized to the World Health Organization’s 2000 standard population.
Fig. 3Prevalence trend of the main comorbidity in patients with UTUC in 2001–2010. (a) DM and (b) ESKD.
Fig. 4Univariate local indicators of spatial association cluster maps for Taiwan UTUC incidence, 2001–2010. High‐high represents that a township with high UTUC incidence is surrounded by neighbors with high UTUC incidence; low‐low represents that a township with low UTUC incidence is surrounded by neighbors with low UTUC incidence; low‐high represents that a township with low UTUC incidence is surrounded by neighbors with high UTUC incidence; and high‐low represents that a township with high UTUC incidence is surrounded by neighbors with low UTUC incidence. The remaining 19 townships had no neighboring townships.
Five‐year survival probabilities in patients newly diagnosed with UTUC in the 2001–2005 cohort
| Case number | Overall | Cancer‐specific | |||||
|---|---|---|---|---|---|---|---|
| No. deaths | Survival probability |
| No. deaths | Survival probability |
| ||
| Overall | 3870 | 2349 | 48.0 | – | 341 | 79.5 | – |
| Age at diagnosis (years) | <0.001 | <0.001 | |||||
| 0–44 | 162 | 45 | 77.8 | 6 | 95.1 | ||
| 45–54 | 441 | 155 | 73.7 | 18 | 94.4 | ||
| 55–64 | 836 | 411 | 64.6 | 49 | 90.1 | ||
| 65–74 | 1365 | 876 | 53.0 | 120 | 80.8 | ||
| ≥75 | 1066 | 862 | 33.9 | 148 | 58.2 | ||
| Sex | 0.002 | 0.37 | |||||
| Male | 1777 | 1114 | 51.0 | 158 | 81.1 | ||
| Female | 2093 | 1235 | 55.9 | 183 | 82.8 | ||
| Urbanization level | <0.001 | 0.05 | |||||
| Rural | 1250 | 820 | 49.5 | 114 | 79.4 | ||
| Urban | 2620 | 1529 | 55.6 | 227 | 83.2 | ||
| Cohort period (years) | 0.01 | 0.15 | |||||
| 2001–2003 | 2205 | 1391 | 54.0 | 199 | 81.1 | ||
| 2004–2005 | 1665 | 958 | 53.2 | 142 | 83.3 | ||
| Comorbidity | |||||||
| Hypertension | <0.001 | 0.01 | |||||
| No | 2332 | 1325 | 56.0 | 201 | 83.6 | ||
| Yes | 1538 | 1024 | 50.1 | 140 | 79.2 | ||
| DM | <0.001 | 0.13 | |||||
| No | 3216 | 1899 | 54.9 | 285 | 82.6 | ||
| Yes | 654 | 450 | 47.7 | 56 | 78.9 | ||
| ESKD | 0.007 | 0.66 | |||||
| No | 3472 | 2077 | 54.0 | 316 | 81.9 | ||
| Yes | 398 | 272 | 50.8 | 25 | 83.4 | ||
| Tumor grade | <0.001 | <0.001 | |||||
| Low | 170 | 77 | 72.4 | 15 | 86.1 | ||
| Intermediate | 837 | 427 | 67.0 | 46 | 89.9 | ||
| High | 857 | 543 | 50.1 | 76 | 80.5 | ||
| Anaplastic | 565 | 332 | 53.1 | 54 | 81.5 | ||
| Undermine | 1441 | 970 | 46.0 | 150 | 76.8 | ||
The cumulative 5‐year survival probability was estimated using Kaplan–Meier survival analysis, and the difference between subgroups tested using the log‐rank test.
Hazard ratios of 5‐year overall and cancer‐specific mortality in patients newly diagnosed with UTUC in the 2001–2005 cohort
| Overall | Cancer‐specific | |||
|---|---|---|---|---|
| Adjusted hazard ratio (95% CI) |
| Adjusted hazard ratio (95% CI) |
| |
| Age at diagnosis (years) | ||||
| 0–44 | 1.00 [Reference] | 1.00 [Reference] | ||
| 45–54 | 1.32 (0.90–1.93) | 0.16 | 1.19 (0.43–3.25) | 0.74 |
| 55–64 | 2.13 (1.49–3.06) | <0.001 | 2.00 (0.78–5.10) | 0.15 |
| 65–74 | 3.04 (2.14–4.34) | <0.001 | 3.76 (1.51–9.38) | 0.004 |
| ≥75 | 4.93 (3.46–7.04) | <0.001 | 9.28 (3.73–23.10) | <0.001 |
| Sex | ||||
| Female | 1.00 [Reference] | 1.00 [Reference] | ||
| Male | 1.24 (1.12–1.36) | <0.001 | 1.25 (0.97–1.61) | 0.08 |
| Urbanization level | ||||
| Rural | 1.00 [Reference] | 1.00 [Reference] | ||
| Urban | 1.08 (0.98–1.19) | 0.14 | 1.19 (0.92–1.56) | 0.19 |
| Cohort period (years) | ||||
| 2001–2003 | 1.00 [Reference] | 1.00 [Reference] | ||
| 2004–2005 | 1.12 (1.00–1.25) | 0.05 | 0.70 (0.52–0.94) | 0.02 |
| Comorbidity | ||||
| Hypertension | ||||
| No | 1.00 [Reference] | 1.00 [Reference] | ||
| Yes | 1.06 (0.96–1.17) | 0.26 | 1.22 (0.93–1.59) | 0.15 |
| Diabetes | ||||
| No | 1.00 [Reference] | 1.00 [Reference] | ||
| Yes | 1.13 (1.00–1.28) | 0.04 | 0.83 (0.58–1.20) | 0.33 |
| ESKD | ||||
| No | 1.00 [Reference] | 1.00 [Reference] | ||
| Yes | 1.57 (1.36–1.82) | <0.001 | 1.25 (0.73–2.14) | 0.42 |
| Tumor grade | ||||
| Low | 1.00 [Reference] | 1.00 [Reference] | ||
| Intermediate | 1.09 (0.85–1.39) | 0.50 | 0.70 (0.39–1.26) | 0.24 |
| High | 1.62 (1.27–2.06) | <0.001 | 1.37 (0.79–2.39) | 0.27 |
| Anaplastic | 1.53 (1.19–1.97) | 0.001 | 1.49 (0.83–2.69) | 0.18 |
| Undermine | 1.31 (1.02–1.69) | 0.03 | 1.61 (0.90–2.88) | 0.11 |
The results were obtained by multivariable Cox proportional hazards model.